Clinical Trials Sponsored by CytomX Therapeutics

Total 6249 results

CytomX Therapeutics

Completed

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Head and Neck Cancer | Esophageal Cancer | Non Small Cell Lung Cancer | Diffuse Large B Cell Lymphoma | Solid Tumor, Adult

United States, Spain, Korea, Republic of, United Kingdom
CytomX Therapeutics

Terminated

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Solid Tumor, Adult

United States, Spain, Netherlands, United Kingdom
CytomX Therapeutics

Completed

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

United States, Netherlands, Poland, Spain, Ukraine, United Kingdom
CytomX Therapeutics

Terminated

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Solid Tumor | Unresectable or Metastatic Melanoma

Korea, Republic of, United States, Netherlands, Spain, Australia
CytomX Therapeutics

Withdrawn

PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors

Solid Tumor, Adult

United States
CytomX Therapeutics

Recruiting

First In Human Study of CX-2051 in Advanced Solid Tumors

Solid Tumor, Adult

United States
CytomX Therapeutics

Recruiting

A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

Solid Tumors

United States
CytomX Therapeutics

Completed

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Neoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 Negative

United States, Spain, Korea, Republic of
Cytori Therapeutics

Completed

Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA)

Myocardial Ischemia

United States
Cytori Therapeutics

Completed

Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II) (ATHENA II)

Myocardial Ischemia

United States
Cytori Therapeutics

Withdrawn

Registry of Celution Device for Processing ADRCs and Healing in Muscle and Ligament Sports Injuries (ACHILLES)

Muscle Tear

United Kingdom
Cytori Therapeutics

Withdrawn

Cardiac REgistry of Celution Device for the Processing of Adipose-derived Regenerative Cells (CREATE)

Coronary Artery Disease | Heart Failure
Cytori Therapeutics

Completed

Feasibility of Obtaining ADRCs From Discarded Thermal Burn Eschar Tissue Using Investigational Celution® System

Thermal Burn

United States
Cytori Therapeutics

Completed

Randomized Clinical Trial of Adipose-Derived Stem Cells in the Treatment of Pts With ST-elevation Myocardial Infarction

Myocardial Infarction | Coronary Disease | Cardiovascular Disease | Coronary Arteriosclerosis

Spain, Netherlands
Cytori Therapeutics

Suspended

Safety and Feasibility of ADRCs Treatment To Patients With Thermal Wounds

Thermal Burn

United States
Cytori Therapeutics

Completed

Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee (ACT-OA Knee)

Osteoarthritis, Knee

United States
Cytori Therapeutics

Completed

Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy (RESTORE-2)

Breast Neoplasms | Carcinoma, Ductal, Breast | Mammaplasty | Mastectomy, Segmental, Lumpectomy, Breast Reconstruction,

Spain, United Kingdom, Belgium, Italy
Cytori Therapeutics

Completed

Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR) (STAR)

Systemic Sclerosis | Scleroderma | Raynaud Phenomena | Raynaud's Disease

United States
Cytori Therapeutics

Withdrawn

Registry of Celution Device for the Processing of Adipose Derived Regenerative Cells (ADRCs) to Treat Osteoarthritis (RELIEVE)

Osteoarthritis
Cytori Therapeutics

Unknown

Characterization of Adipose Derived Regenerative Cells (ADRCs) From Patients With Chronic Heart Disease

Chronic Heart Failure

United States
Cytori Therapeutics

Withdrawn

Scleroderma Treatment With Celution Processed ADRCs Registry (STAR)

Scleroderma
Cytori Therapeutics

Completed

Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI) (ADVANCE)

Acute Myocardial Infarction

Netherlands, Poland
Cytori Therapeutics

Withdrawn

Safety and Feasibility of ADRCs (Adipose Derived Regenerative Cells) in Patients With Grade II Hamstring Tears (RECOVER)

Muscle Tear

United States
Cytori Therapeutics

Completed

A Randomized Clinical Trial of Adipose-derived Stem Cells in Treatment of Non Revascularizable Ischemic Myocardium

Coronary Artery Disease | Coronary Disease | Cardiovascular Disease | Ischemic Heart Disease | Coronary Arteriosclerosis

Spain, Denmark, Netherlands
Cytori Therapeutics

Completed

SurgiWrapTM to Reduce Soft Tissue Attachment & Incidence Early Post-Operative Bowel Obstruction in Colorectal Surgery

Colectomy | Adhesions

United States
CytoMed Therapeutics Pte Ltd

Unknown

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Sarcoma | Nasopharyngeal Carcinoma | Gastric Cancer | Colorectal Cancer | Prostate Cancer | Triple Negative Breast Cancer

Malaysia
Mast Therapeutics, Inc.
CytRx

Completed

Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease

Sickle Cell Anemia
Winthrop University Hospital
Cytori Therapeutics

Withdrawn

Adipose-derived Stem Cells to Treat Chronic Wounds.

Wound of Skin

United States
Cyto Therapeutics Pty Limited

Unknown

A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease

Parkinson Disease

Australia
CytoMed Therapeutics Pte Ltd
National University Hospital, Singapore

Not yet recruiting

Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)

Cancer | Malignancy | Relapsed Cancer | Refractory Cancer

Singapore
Landmark Medical Centre Sdn Bhd
CytoMed Therapeutics Pte Ltd

Unknown

MSC Infusion for Anti-aging and Regenerative Therapy (REGEN)

Aging Well | Regenerative Medicine

Malaysia
Cytora Ltd.

Recruiting

Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early- to Moderate Stage MSA

Multiple System Atrophy | MSA - Multiple System Atrophy

Israel
Cytora Ltd.

Active, not recruiting

Study for Treatment of Chronic Diabetic Foot Ulcers With the Investigational Allogeneic Cell Therapy Product, hOMSC200

Diabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic

Israel
CytoMed & Beike

Unknown

Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis (hUC-MSC-SLE)

Lupus Nephritis

China
CytRx

No longer available

Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy

Sarcoma

United States
CytRx

Completed

Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL (STAR-1)

Acute Promyelocytic Leukemia

United States
CytRx

Withdrawn

INNO-206 in Patients With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

United States
CytRx

Completed

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

Amyotrophic Lateral Sclerosis (ALS)

United States
CytRx

Unknown

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

Metastatic Small Cell Lung Cancer

United States, Spain, Hungary
CytRx

Unknown

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue Sarcoma

United States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
CytRx

Completed

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma

United States
CytRx

Terminated

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion

United States, Mexico, India, Ukraine, Bulgaria, Russian Federation
CytRx

Completed

Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

B-Cell Chronic Lymphocytic Leukemia

United States
CytRx

Withdrawn

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

Amyotrophic Lateral Sclerosis

United States, Canada
CytRx

Completed

Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer (PROACT)

Hormone Refractory Prostate Cancer

United States
CytRx

Completed

Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia

Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia

United States, Israel, Germany
Cytos Biotechnology AG

Withdrawn

CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids

Asthma

United States
Cytos Biotechnology AG

Completed

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

House Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis

Switzerland
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

Malignant Melanoma

Switzerland
Cytos Biotechnology AG

Terminated

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Moderate to Severe Allergic Asthma

United States, Czech Republic, Germany, Hungary, Israel, Poland, Russian Federation, Ukraine

3

Subscribe